BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huijser E, Göpfert J, Brkic Z, van Helden-Meeuwsen CG, Jansen S, Mandl T, Olsson P, Schrijver B, Schreurs MWJ, van Daele PLA, Dik WA, Versnel MA. Serum IFNα2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome. Rheumatology (Oxford) 2021:keab688. [PMID: 34505866 DOI: 10.1093/rheumatology/keab688] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Cooles FAH, Tarn J, Lendrem DW, Naamane N, Lin CM, Millar B, Maney NJ, Anderson AE, Thalayasingam N, Diboll J, Bondet V, Duffy D, Barnes MR, Smith GR, Ng S, Watson D, Henkin R, Cope AP, Reynard LN, Pratt AG, Isaacs JD; RA-MAP Consortium. Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. Ann Rheum Dis 2022:annrheumdis-2022-222370. [PMID: 35680389 DOI: 10.1136/annrheumdis-2022-222370] [Reference Citation Analysis]
2 Jansen MP, Mastbergen SC. Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms. Nat Rev Rheumatol 2021. [PMID: 34616035 DOI: 10.1038/s41584-021-00695-y] [Reference Citation Analysis]
3 Huijser E, van Helden-meeuwsen CG, Grashof DGB, Tarn JR, Brkic Z, Huisman JMA, Wahadat MJ, van de Werken HJG, Lopes AP, van Roon JAG, van Daele PLA, Kamphuis S, Ng W, Bekkering S, Joosten LAB, Dik WA, Versnel MA. Trained Immunity in Primary Sjögren’s Syndrome: Linking Type I Interferons to a Pro-Atherogenic Phenotype. Front Immunol 2022;13:840751. [DOI: 10.3389/fimmu.2022.840751] [Reference Citation Analysis]